CAMERON WAGENBRENNER: Open Payments
NPI 1063995561 · COLBERT, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 29 payments from 12 companies in 2025. Trend: 2023 $614 · 2024 $639 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Exact Sciences Corporation | 4 | $82 |
| Corcept Therapeutics | 4 | $80 |
| ABBVIE INC. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Braeburn Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $28 |
Products named: REXULTI, Korlym, CAPLYTA, Cologuard Collection Kit, BRIXADI, The Cologuard Plus Collection Kit, VRAYLAR, FARXIGA.
Industry payments across GA — which companies pay providers there.
